Dengue
Conditions
Interventions
According to the protocol, 1800 participants will undergo medical procedures, such as blood sample drawing and medical care, such as medical consult/visits. A blood sample for serology will be collect
Other
E01.370.225.998.110
Sponsors
GlaxoSmithKline Biologicals
GlaxoSmithKline Biologicals
Eligibility
Age
6 Months to 110 Years
Inclusion criteria
Inclusion criteria: Written and signed informed consent; male or female at least 6 months of age at the time of enrollment; subject and/or subject’s parent(s) who the investigator believes can comply with the requirements of the protocol and Subject who plans, at the time of enrollment, to remain at same residence/study area during the one year study period
Exclusion criteria
Exclusion criteria: Child in care; participation (current or planned) in another epidemiological study or in a clinical trial that would conflict with the current study, based on investigator’s judgement and terminal illness or severe mental incapacity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the incidence of laboratory-confirmed symptomatic dengue infection (all DENV types) | — |
Secondary
| Measure | Time frame |
|---|---|
| Estimate the incidence of DENV-type specific laboratory-confirmed and probable symptomatic dengue infection by study site, gender, age-group, and previous dengue exposure (primary or secondary); estimate the prevalence of previous dengue infection(s) (dengue seroprevalence) at baseline; estimate the incidence of primary inapparent dengue infection and estimate the severity of symptomatic dengue (using the 2009 WHO guidelines). | — |
Countries
Brazil
Contacts
Public ContactEliana;Serviço de Atendimento ao Cliente de Barros;SAC
GlaxoSmithKline Brasil Ltda;GlaxoSmithKline Brasil Ltda
Outcome results
None listed